A prospective, observational study of rivaroxaban for stroke prevention in atrial fibrillation: the XANAP Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shim, Jaemin | - |
dc.contributor.author | On, Young Keun | - |
dc.contributor.author | Kwon, Sun U. | - |
dc.contributor.author | Nam, Gi-Byoung | - |
dc.contributor.author | Lee, Moon-Hyoung | - |
dc.contributor.author | Park, Hyung-Wook | - |
dc.contributor.author | Hong, Keun-Sik | - |
dc.contributor.author | Kim, Nam-Ho | - |
dc.contributor.author | Amarenco, Pierre | - |
dc.contributor.author | Rha, Seung-Woon | - |
dc.contributor.author | Shin, Dong-Gu | - |
dc.contributor.author | Rha, Joung-Ho | - |
dc.contributor.author | Kim, Young-Hoon | - |
dc.date.accessioned | 2022-02-28T08:42:09Z | - |
dc.date.available | 2022-02-28T08:42:09Z | - |
dc.date.created | 2022-02-09 | - |
dc.date.issued | 2021-07 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/137234 | - |
dc.description.abstract | Background Aims: Atrial fibrillation (AF)-related stroke accounts for 20% of ischemic strokes. Rivaroxaban use in AF patients for preventing stroke and systemic embolism was approved in 2013 in Korea. This study was to investigate the safety and effectiveness of rivaroxaban use in Korean patients with non-valvular AF in a real-world setting. Methods: This was an analysis of the Korean patients in Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation in Asia-Pacific (XANAP), which was a prospective, observational cohort study including patients with non-valvular AF starting rivaroxaban treatment to prevent stroke or non-central nervous system systemic embolism (non-CNS SE), conducted in 10 Asian countries. Results: A total of 844 patients were enrolled in the Korean portion of the XANAP study. In XANAP Korea, the mean age was 70.1 years and 62.6% were males. The mean CHADS(2) score was 2.5 and the mean CHA(2)DS(2)-VASc score was 3.8. 47% of the patients had experienced prior stroke or non-CNS SE or transient ischemic attack. 73.6% of the patients had CHADS(2) score >= 2. Incidence proportions of 0.8% of the patients (1.1 per loo patient-years) developed adjudicated treatment-emergent major bleeding. Death was observed in 1.2% of the patients. The incidence of non-major bleeding as well as thromboembolic event were 8.4% (11.6 per 100 patient-years) and 1.5% (2.0 per 100 patient-years), respectively. Conclusions: This study reaffirmed the consistent safety profile of rivaroxaban. We found consistent results with overall XANAP population for rivaroxaban in terms of safety in non-valvular AF patients for the prevention of stroke and non-CNS SE. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ASSOC INTERNAL MEDICINE | - |
dc.subject | ASIAN PATIENTS | - |
dc.subject | ORAL ANTICOAGULANTS | - |
dc.subject | PREVALENCE | - |
dc.subject | TRENDS | - |
dc.title | A prospective, observational study of rivaroxaban for stroke prevention in atrial fibrillation: the XANAP Korea | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Rha, Seung-Woon | - |
dc.identifier.doi | 10.3904/kjim.2020.217 | - |
dc.identifier.scopusid | 2-s2.0-85110270080 | - |
dc.identifier.wosid | 000669004600020 | - |
dc.identifier.bibliographicCitation | KOREAN JOURNAL OF INTERNAL MEDICINE, v.36, no.4, pp.906 - 913 | - |
dc.relation.isPartOf | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.citation.title | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.citation.volume | 36 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 906 | - |
dc.citation.endPage | 913 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002728042 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | ASIAN PATIENTS | - |
dc.subject.keywordPlus | ORAL ANTICOAGULANTS | - |
dc.subject.keywordPlus | PREVALENCE | - |
dc.subject.keywordPlus | TRENDS | - |
dc.subject.keywordAuthor | Atrial fibrillation | - |
dc.subject.keywordAuthor | Korea | - |
dc.subject.keywordAuthor | Rivaroxaban | - |
dc.subject.keywordAuthor | Stroke | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.